Therapy News and Research

RSS

Targeting ZBP1 may overcome cancer immunotherapy resistance

A new Review published in the open-access journal Ferroptosis and Oxidative Stress highlights Z-nucleic acid-binding protein 1 (ZBP1) as an emerging innate immune sensor that converts genomic stress into potent antitumor immunity.

16 Jul 2026

Long-term lenalidomide maintenance shows no survival advantage in multiple myeloma

For patients with newly diagnosed multiple myeloma not undergoing an autologous stem cell transplant, indefinite lenalidomide maintenance has long been standard care despite limited evidence to guide the optimal duration of treatment.

16 Jul 2026

Novel DNA nanoplatform offers hope for chronic gum disease

Millions of people worldwide live with periodontitis, a chronic gum disease that can progressively destroy the tissues and bone supporting the teeth despite conventional treatment.

16 Jul 2026

Fractyl Health reports positive randomized data from REMAIN-1 Midpoint Cohort demonstrating durable weight maintenance one year after GLP-1 discontinuation

Fractyl Health, Inc. (Fractyl), a clinical-stage metabolic therapeutics company focused on pioneering novel approaches to treat obesity and type 2 diabetes (T2D), today announced positive one-year results from its REMAIN-1 Midpoint Cohort (“Midpoint Cohort”).

16 Jul 2026

Extended myeloma maintenance therapy shows no additional survival benefit

A major national cooperative group clinical trial led by Mayo Clinic researchers found that continuing maintenance therapy with lenalidomide beyond two years after initial treatment for standard-risk multiple myeloma did not improve overall survival compared with stopping treatment after two years.

15 Jul 2026

Researchers uncover new T cell attack mechanism against acute myeloid leukemia

Researchers at The University of Texas MD Anderson Cancer Center have discovered a new way in which T cells attack acute myeloid leukemia (AML) cells, which may help explain why AML is particularly sensitive to immune-based treatments and could guide the development of future cancer immunotherapies.

15 Jul 2026

AI model predicts effective immunotherapy combinations for liver cancer

Using computational tools, researchers from the Johns Hopkins Kimmel Cancer Center and the Johns Hopkins University School of Medicine have developed a method to predict which patients with a primary liver cancer called hepatocellular carcinoma (HCC) would most benefit from combination treatment using immunotherapy and a targeted therapy that blocks the growth signals that the tumor depends on.

15 Jul 2026

Self-assembling antibody drugs successfully target multiple cancer receptors

Modern anticancer medications that combine tumor-fighting drugs with proteins that specifically target cancer cells are a relatively new class of drug, often given to patients for whom standard chemotherapy has not worked.

15 Jul 2026

New photoswitchable drugs restore light perception in blind animals

Blinding diseases caused by the degeneration of photoreceptors, such as age-related macular degeneration (AMD) and retinitis pigmentosa (RP), affect 200 million people worldwide and represent the leading causes of visual impairment and blindness.

15 Jul 2026

AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition

AbbVie's strategic acquisition of Apogee Therapeutics highlights its commitment to advancing immunology and developing next-generation treatments for patients.

From 10th Dermatology Drug Development Summit 15 Jul 2026

Europe’s fragmented early access landscape intensifies need for operational strategy ahead of the 5th Operationalise: Early Access Programmes Summit Europe

Join industry leaders at the 2026 summit to discuss strategies for navigating early access programmes and improving patient access to investigational therapies.

From 5th Operationalise: Early Access Programmes Summit Europe 15 Jul 2026

More than 50 million Americans lack local radiation cancer treatment

The disappearance of radiation oncology clinics threatens cancer care access for over 50 million Americans, with rural areas facing the greatest impact.

15 Jul 2026

Breast and prostate cancer survival worsens with metabolic syndrome

A SEER-Medicare analysis of more than 200,000 adults aged 66 and older found that metabolic syndrome was associated with about twice the adjusted hazard of death from any cause after breast or prostate cancer. The condition was also linked to higher cancer-specific, cardiovascular-specific, and liver-failure-specific mortality, although the observational design prevents causal conclusions.

14 Jul 2026